Park Avenue Institutional Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

Park Avenue Institutional Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,420	Closed	-$166K	–	450
2016 Q2	$166K	Hold	1,420	–	–	0.14%	171
2016 Q1	$198K	Sell	1,420 -40	-3%	-$5.87K	0.17%	145
2015 Q4	$278K	Sell	1,460 -44	-3%	-$7.69K	0.24%	100
2015 Q3	$235K	Buy	1,504 +140	+10%	+$25.5K	0.21%	118
2015 Q2	$247K	Buy	+1,364	New	+$235K	0.2%	129

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Park Avenue Institutional Advisers's ALXN Position: Q3 2016 in Review

Park Avenue Institutional Advisers sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 1,420 shares — an estimated $166K sold.

Park Avenue Institutional Advisers first reported a position in ALXN in Q2 2015 and held it in 5 quarters. The position peaked at $278K in Q4 2015. 518 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

Park Avenue Institutional Advisers reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Park Avenue Institutional Advisers sold 1,420 Alexion Pharmaceuticals shares in Q3 2016, an estimated $166K.
Park Avenue Institutional Advisers first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Park Avenue Institutional Advisers's Alexion Pharmaceuticals position peaked at $278K in Q4 2015.
518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Park Avenue Institutional Advisers's 13F filing for Q3 2016, filed 15 Feb 2017.